The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Phase II TALTEC: bispecific T-cell redirectors in frontline therapy for transplant-eligible myeloma
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, comments on the Phase II TALTEC study (NCT06505369), investigating the use of talquetamab and teclistamab as part of first-line treatment in patients with transplant-eligible multiple myeloma. The study aims to evaluate the efficacy of consolidating with 6 cycles of talquetamab and 6 cycles of teclistamab after 6 cycles of Dara-VRd. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The TALTEC study is a Phase II study run by the Nordic Group sponsored by Diana Loigom in Estonia, Tallinn. This is a frontline trial for patients who are newly diagnosed with myeloma and transplant eligible. So we’re trying to make Phase II data to give data to support a Phase III trial where we, instead of doing transplant, we consolidate with 6 cycles of talquetamab and then 6 cycles of teclistamab...
The TALTEC study is a Phase II study run by the Nordic Group sponsored by Diana Loigom in Estonia, Tallinn. This is a frontline trial for patients who are newly diagnosed with myeloma and transplant eligible. So we’re trying to make Phase II data to give data to support a Phase III trial where we, instead of doing transplant, we consolidate with 6 cycles of talquetamab and then 6 cycles of teclistamab. So we’re doing first 6 cycles of Dara-VRd, that’s the standard, but instead of going to transplant, we’re giving 6 cycles of talquetamab and then 6 cycles of teclistamab. So the primary endpoint will be MRD negativity CR after these three sequences, Dara-VRd, talquetamab and teclistamab. Currently, the study is fully enrolled this spring. The majority of patients are now into the talquetamab sequence, but we still have patients on Dara-VRd. So we don’t have the primary results yet. We’re going to have MRD endpoints after Dara-VRd, and after talquetamab, and after teclistamab. So we’re showing now the trial here at IMS as a poster. That’s a trial in progress, the design of the trial. But the results will not be ready yet. But next year, maybe we’ll see something.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
